PARP1 and ovarian cancer: The DNA repair‐associated resistance mechanisms to PARP inhibition have been well characterized in breast and ovarian cancers (D'Andrea, 2018), and it is reasonable to predict that similar mechanisms may promote resistance in CRC patients following PARP blockade.